The Senate Health, Education, Labor & Pensions Committee last night voted 13-9 to advance legislation that would reauthorize Food and Drug Administration user fee programs and modify the regulatory framework for laboratory developed tests. AHA last week urged lawmakers to consider certain changes to the LDT provisions to ensure continued access to these critical tests.  
 
The House last week passed its own bill (H.R. 7667) to reauthorize FDA user fee programs, which does not include the LDT provisions. Among other provisions, the House bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. 
 

Related News Articles

Headline
The Senate yesterday voted 51-50 to pass the Inflation Reduction Act (H.R. 5376), a roughly $700 billion social spending package that includes health care,…
Headline
The Senate this weekend is expected to take up the Inflation Reduction Act (H.R. 5376), the latest version of the Build Back Better Act, a roughly $700 billion…
Headline
The House Appropriations Committee today voted 32-24 to approve legislation that would provide $242.1 billion in funding for the departments of Labor, Health…
Headline
AHA Friday urged lawmakers to consider certain changes to the Verifying Accurate Leading-Edge IVCT Development (VALID) Act, legislation that would modify the…
Headline
AHA yesterday voiced support for H. Res. 909, which condemns violence against health care workers and expresses support for health care personnel. “The…
Headline
Without additional funding from Congress, the U.S. cannot secure sufficient COVID-19 vaccine boosters and variant-specific vaccines for all Americans;…